|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|ATC code||N01BB10 (WHO)|
|Biological half-life||2–2.6 hours|
|Excretion||Renal 70%, faecal 24%|
|Chemical and physical data|
|Molar mass||288.43 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 percent less potent (by molarity) than racemic bupivacaine and has a longer motor block onset time.
Levobupivacaine is contraindicated for IV regional anaesthesia (IVRA).
Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.
Systemic exposure to excessive quantities of bupivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.
- Burlacu CL, Buggy DJ (April 2008). "Update on local anesthetics: focus on levobupivacaine". Ther Clin Risk Manag. 4 (2): 381–92. PMC 2504073. PMID 18728849.
- Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- Gulec D (Apr 2014). "Intrathecal bupivacaine or levobupivacaine: which should be used for elderly patients?.". J Int Med Res. 42 (2): 376–385. doi:10.1177/0300060513496737. PMID 24595149.